LON:INDV

Indivior - INDV Share Forecast, Price & News

GBX 1,961

+6.00 (+0.31%)

(As of 01/30/2023 12:00 AM ET)

Add

Compare

Today's Range: 1,915
▼
1,973
50-Day Range: 1,685
▼
2,015.33
52-Week Range: 1,052
▼
2,020

Volume: 179,549 shs
Average Volume: 357,916 shs
Market Capitalization: £2.68 billion

P/E Ratio: 8,913.64
Dividend Yield: N/A
Price Target: GBX 330

About Indivior (LON:INDV) Stock

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Receive INDV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter.

INDV Stock News Headlines

January 25, 2023 | americanbankingnews.com

Indivior (LON:INDV) Reaches New 1-Year High at $1,999.00

January 2, 2023 | finance.yahoo.com

Investing in Indivior (LON:INDV) three years ago would have delivered you a 861% gain

January 31, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

December 9, 2022 | finance.yahoo.com

Should You Be Excited About Indivior PLC's (LON:INDV) 73% Return On Equity?

December 7, 2022 | finance.yahoo.com

Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth Outlook

November 14, 2022 | finance.yahoo.com

Indivior To Acquire Opiant Pharmaceuticals

November 8, 2022 | finance.yahoo.com

Indivior Third Quarter 2022 Earnings: EPS: US$0.29 (vs US$0.18 in 3Q 2021)

October 27, 2022 | finance.yahoo.com

Indivior Announces Q3 2022 Financial Results

January 31, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

October 11, 2022 | finance.yahoo.com

Indivior PLC (LON:INDV) is favoured by institutional owners who hold 86% of the company

September 30, 2022 | finance.yahoo.com

Indivior Shareholders Approve Resolutions to Proceed with Additional U.S. Listing

September 27, 2022 | businesswire.com

Aelis Farma: Availability of the 2022 Half-year Financial Report - Business Wire

September 7, 2022 | finance.yahoo.com

Indivior To Participate in Upcoming Investor Healthcare Events

August 30, 2022 | nasdaq.com

Is EDAP TMS (EDAP) Outperforming Other Medical Stocks This Year? - Nasdaq

August 25, 2022 | finance.yahoo.com

Indivior Publishes Exploratory Study Showing That Access to Medication for Opioid Use Disorder Varies Across Organized Health Systems in the U.S.

August 15, 2022 | seekingalpha.com

Addex, Indivior expand team up to develop therapies for substance use disorders - Seeking Alpha

August 15, 2022 | globenewswire.com

Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders - GlobeNewswire

August 15, 2022 | finance.yahoo.com

These 4 Measures Indicate That Indivior (LON:INDV) Is Using Debt Reasonably Well

August 12, 2022 | finance.yahoo.com

Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022 - Yahoo Finance

August 9, 2022 | finance.yahoo.com

CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors - Yahoo Finance

July 30, 2022 | morningstar.co.uk

Indivior shares down amid drop in interim profit; eyes US listing - Morningstar

July 28, 2022 | benzinga.com

Indivior Announces H1 and Q2 2022 Financial Results - Benzinga

July 28, 2022 | finance.yahoo.com

Indivior Announces H1 and Q2 2022 Financial Results

July 27, 2022 | finance.yahoo.com

Addex Completes $4.2 Million Equity Financing - Yahoo Finance

July 26, 2022 | finance.yahoo.com

Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs - Yahoo Finance

July 25, 2022 | uk.finance.yahoo.com

Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs - Yahoo Finance UK

July 24, 2022 | finance.yahoo.com

Indivior (LON:INDV) shareholders have earned a 80% CAGR over the last three years

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive INDV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter.

INDV Company Calendar

Today: 1/31/2023
Next Earnings (Estimated): 2/14/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Drugs - Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:INDV
CUSIP: N/A
CIK: N/A
Web: indivior.com
Phone: +44-1753-217800
Fax: N/A
Employees: 885
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: GBX 330
High Stock Price Forecast: GBX 330
Low Stock Price Forecast: GBX 330
Forecasted Upside/Downside: -83.2%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: 8,913.64
Forward P/E Ratio: 1,850.00
P/E Growth: -5.57
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 121.59
Current Ratio: 1.70
Quick Ratio: 1.52

Sales & Book Value

Annual Sales: £882 million
Price / Sales: 3.03
Cash Flow: GBX 731.69 per share
Price / Cash Flow: 2.68
Book Value: GBX 164.80 per share
Price / Book: 11.90

Miscellaneous

Outstanding Shares: 136,481,000
Free Float: N/A
Market Cap: £2.68 billion
Optionable: Not Optionable
Beta: N/A

Key Executives

Mr. Mark Crossley
CEO & Exec. Director

Mr. Ryan Preblick
CFO & Exec. Director

Dr. Christian Heidbreder
Chief Scientific Officer

Mr. Jason Thompson
VP of Investor Relations

Ms. Cynthia Cetani
Chief Integrity & Compliance Officer

Mr. Jeffrey W. Burris (Age 51)
Chief Legal Officer

Mr. Jon Fogle
Chief HR Officer

Mr. Richard Simkin
Chief Commercial & Strategy Officer

Mr. Hillel West
Chief Manufacturing & Supply Officer

Ms. Nina DeLorenzo
Chief Global Impact Officer

Key Competitors

View All Competitors

INDV Stock - Frequently Asked Questions

Should I buy or sell Indivior stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" INDV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INDV, but not buy additional shares or sell existing shares.
View INDV analyst ratings or view top-rated stocks.
What is Indivior's stock price forecast for 2023?: 1 equities research analysts have issued 12-month price objectives for Indivior's shares. Their INDV share price forecasts range from GBX 330 to GBX 330. On average, they anticipate the company's share price to reach GBX 330 in the next twelve months. This suggests that the stock has a possible downside of 83.2%.
View analysts price targets for INDV or view top-rated stocks among Wall Street analysts.
How have INDV shares performed in 2023?: Indivior's stock was trading at GBX 1,852 at the beginning of the year. Since then, INDV shares have increased by 5.9% and is now trading at GBX 1,961.
View the best growth stocks for 2023 here.
When is Indivior's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023.
View our INDV earnings forecast.

What other stocks do shareholders of Indivior own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Indivior investors own include Bigblu Broadband (BBB), Futura Medical (FUM), Directa Plus (DCTA), Lakehouse (LAKE), Aquila Services Group (AQSG), Benchmark (BMK), Bodycote (BOY), CityFibre Infrastructure (CITY), Deltex Medical Group (DEMG) and Kingfisher (KGF).
What is Indivior's stock symbol?: Indivior trades on the London Stock Exchange (LON) under the ticker symbol "INDV."
How do I buy shares of Indivior?: Shares of INDV stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Indivior's stock price today?: One share of INDV stock can currently be purchased for approximately GBX 1,961.
How much money does Indivior make?: Indivior (LON:INDV) has a market capitalization of £2.68 billion and generates £882 million in revenue each year.
How many employees does Indivior have?: The company employs 885 workers across the globe.
How can I contact Indivior?: Indivior's mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The official website for the company is indivior.com. The specialty pharmaceutical company can be reached via phone at +44-1753-217800.

This page (LON:INDV) was last updated on 1/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial